Trial Profile
Long term follow up of the immunogenicity of 7-valent pneumococcal conjugate vaccine (PCV-7) vs 23-valent pneumococcal polysaccharide vaccine (23vPPV) PPV in vulnerable elderly populations at high risk for invasive pneumococcal disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- 08 Jan 2014 New trial record